These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29650092)

  • 61. Clinical application of C-reactive protein for cardiovascular disease detection and prevention.
    Ridker PM
    Circulation; 2003 Jan; 107(3):363-9. PubMed ID: 12551853
    [No Abstract]   [Full Text] [Related]  

  • 62. [Too positive comment on glitazones].
    Lindberg M
    Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
    [No Abstract]   [Full Text] [Related]  

  • 63. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Levine BD; Washington RL; Baggish AL; Kovacs RJ; Maron MS;
    Circulation; 2015 Dec; 132(22):e267-72. PubMed ID: 26527714
    [No Abstract]   [Full Text] [Related]  

  • 64. Long-term renal and cardiovascular risk after preeclampsia: towards screening and prevention.
    Paauw ND; Luijken K; Franx A; Verhaar MC; Lely AT
    Clin Sci (Lond); 2016 Feb; 130(4):239-46. PubMed ID: 26769659
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.
    Akhabue E; Rittner SS; Carroll JE; Crawford PM; Dant L; Laws R; Leo MC; Puro J; Persell SD
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673901
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Anti-diabetic therapy and cardiovascular disease].
    Mannucci E
    G Ital Cardiol (Rome); 2016 Mar; 17(3 Suppl 2):3s-4. PubMed ID: 27030117
    [No Abstract]   [Full Text] [Related]  

  • 67. FDA upholds findings of UGDP study.
    JAMA; 1979 Jan; 241(1):17-8. PubMed ID: 758481
    [No Abstract]   [Full Text] [Related]  

  • 68. A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.
    Krumholz HM
    Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):221-2. PubMed ID: 20181986
    [No Abstract]   [Full Text] [Related]  

  • 69. Editorial: Settling the UGDP controversy.
    Chalmers TC
    JAMA; 1975 Feb; 231(6):624-5. PubMed ID: 1172848
    [No Abstract]   [Full Text] [Related]  

  • 70. [Management of the side effects of oral hypoglycemic agents in diabetes mellitus].
    Ishii J; Suzuki M
    Nihon Rinsho; 1990 Dec; 48 Suppl():955-61. PubMed ID: 2086978
    [No Abstract]   [Full Text] [Related]  

  • 71. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Levine BD; Washington RL; Baggish AL; Kovacs RJ; Maron MS
    J Am Coll Cardiol; 2015 Dec; 66(21):2356-2361. PubMed ID: 26542659
    [No Abstract]   [Full Text] [Related]  

  • 72. Cardiovascular screening in asymptomatic adults: lessons for the diving world.
    Douglas PS
    Undersea Hyperb Med; 2011; 38(4):279-87. PubMed ID: 21877557
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cardiovascular complications and drug prescriptions in subjects with and without diabetes in a Northern region of Italy, in 2002 and 2012.
    Baviera M; Avanzini F; Marzona I; Tettamanti M; Vannini T; Cortesi L; Fortino I; Bortolotti A; Merlino L; Trevisan R; Roncaglioni MC
    Nutr Metab Cardiovasc Dis; 2017 Jan; 27(1):54-62. PubMed ID: 27956023
    [TBL] [Abstract][Full Text] [Related]  

  • 74. American Heart Association guidelines for prevention of pediatric cardiovascular disease.
    Kash IJ
    J Pediatr; 2004 Apr; 144(4):552; author reply 552-3. PubMed ID: 15069413
    [No Abstract]   [Full Text] [Related]  

  • 75. Diabetes: Time for reconciliation between cardiologists and diabetologists.
    Scheen AJ
    Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401
    [No Abstract]   [Full Text] [Related]  

  • 76. [Diabetology 2007].
    Scherbaum WA
    Dtsch Med Wochenschr; 2007 Jun; 132(25-26):1407-10. PubMed ID: 17570091
    [No Abstract]   [Full Text] [Related]  

  • 77. Antidiabetic agents and vascular events.
    Keen H
    J Clin Pathol Suppl (R Coll Pathol); 1975; 9():99-105. PubMed ID: 783218
    [No Abstract]   [Full Text] [Related]  

  • 78. Patients with both diabetes and heart failure often treated with medications government considers unsafe.
    Levenson D
    Rep Med Guidel Outcomes Res; 2003 Aug; 14(15):1, 6-7. PubMed ID: 12964577
    [No Abstract]   [Full Text] [Related]  

  • 79. Incretins: cardiovascular safety and rationale for use.
    Kok A
    Cardiovasc J Afr; 2013 Mar; 24(2):46. PubMed ID: 23750348
    [No Abstract]   [Full Text] [Related]  

  • 80. Paradigm shift in the management of DM & CVD-preventing the next CV event.
    Handelsman Y; Bloomgarden Z
    J Diabetes; 2020 Sep; 12(9):630-632. PubMed ID: 32573096
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.